Patients and experts call for action on World Asthma Day 2024

On World Asthma Day 2024, AstraZeneca stands with the severe asthma community to highlight the condition’s profound impact on patients and healthcare systems. Severe asthma is a distinct form of asthma affecting 3-10% of cases, with up to 57% patients having uncontrolled disease. Hear from advocates Poppy and Tonya as they describe the challenges facing patients today.
To find out more about Respiratory and Immunology - Our therapy areas - AstraZeneca visit our website.
------------------------------------------------------------
Global site: www.astrazeneca.com/
Careers site: careers.astrazeneca.com/
Follow us:
Twitter: / astrazeneca
LinkedIn: / astrazeneca
Instagram: / astrazeneca
Facebook: / astrazenecacareers
References:
1. Chung KF, Wenzel SE, Brozek JL, et al. 2014. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 43(2): 343-73
2. Hekking PW, Wener RR, Amelink M, et al. 2015. The prevalence of severe refractory asthma. J Allergy Clin Immunol 135(4): 896-902
3. Wang E, et al. Characterization of Severe Asthma Worldwide. Chest. 2020;157(4):790-804.